300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Cryptocurrency
Digital Media
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Real Estate
Sporting Goods
Music
Life Science
Art
Finance
Manufacturing
Publishing
FinTech
Social Media
Franchise
Wine and Spirits
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Mobile Apps
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Singapore
Burkina Faso
Africa
LATAM
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
Côte d'Ivoire
China
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Tempus, VC Fund

Tempus

VC Fund

Chicago, United States

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions todeliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Total investments:
5
Last investment:
Lead investor:
60%

Last updated:

Industries Tempus invests in

BiotechnologyGeneticsHealth CareB2BTravel

Stages Tempus invests in

Series ASeries CFunding RoundPost-IPO Equity

Countries Tempus invests in

United StatesSingaporeUnited Kingdom

Contacts

NameEmailPhoneSocials
Jonathan Ozeran Jonathan Ozeran
Andrew Polovin Andrew Polovin
Kimberly Yeatts Kimberly Yeatts
Martin Stumpe Martin Stumpe
See all 9 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 3 (60%)
  • Genetics 2 (40%)
  • Health Care 2 (40%)
  • B2B 1 (20%)
  • Travel 1 (20%)
See all 13 industries →

Stage

  • Series A 1 (20%)
  • Series C 1 (20%)
  • Funding Round 1 (20%)
  • Post-IPO Equity 1 (20%)

Country

  • United States 2 (40%)
  • Singapore 1 (20%)
  • United Kingdom 1 (20%)

Team

NameTitleInvestmentsLinksEmail
Eric Lefkofsky
Eric Lefkofsky Founder and CEO
Founder and CEO Total investments: 84
Find email
Jonathan Ozeran
Jonathan Ozeran Director of Product
Director of Product Total investments: 1
Find email
Andrew Polovin
Andrew Polovin General Counsel
General Counsel Total investments: 0 Find email
Kimberly Yeatts
Kimberly Yeatts Vice President of Clinical Lab Operations
Vice President of Clinical Lab Operations Total investments: 0 Find email
Martin Stumpe
Martin Stumpe Chief of AI
Chief of AI Total investments: 0 Find email
See all 9 team members →

Investments

CompanyDescriptionRoundLinks
Personalis Personalis
Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. $36.1M / Post-IPO Equity / Aug 16, 2024
Akrivia Health Akrivia Health
Akrivia Health provides real-world data for evidence generation, clinical trial optimization, and molecular characterization for mental health and dementia. It also provides assistance in the processes of early-stage drug discovery, market analysis, clinical trial revenue management, and more. $5.9M / Series A / Jun 20, 2021
8Trip 8Trip
8Trip, a China-based online travel service which connects suppliers with sellers. Currently, 8Trip covers the markets of Wuxi, Nanjing, and Anhui in China, and is planning to enter the Shanghai market next year. The company has partnerships with about 1,000 travel agencies and more than 4,000 service outlets. 8Trip was founded in December 2011under the company name Octopus Online Tourism Development, with headquarters in Suzhou. $85M / Series C / Apr 09, 2018
Exicure Exicure
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. $20M / Sep 27, 2017
Exicure Exicure
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. $14.8M / Oct 21, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Cryptocurrency
Digital Media
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Real Estate
Sporting Goods
Music
Life Science
Art
Finance
Manufacturing
Publishing
FinTech
Social Media
Franchise
Wine and Spirits
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Mobile Apps
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Singapore
Burkina Faso
Africa
LATAM
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
Côte d'Ivoire
China
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Tempus invest in?

Tempus invests primarily in Biotechnology, Genetics and Health Care startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Tempus?

Public channels for Tempus include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Tempus?

The team at Tempus includes Eric Lefkofsky (Founder and CEO), Jonathan Ozeran (Director of Product) and Andrew Polovin (General Counsel), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Tempus Tempus Find emails